# R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

> **NCT06594640** · PHASE1,PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 108 (estimated)

## Conditions studied

- Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** Mitoxantrone Hydrochloride Liposome
- **DRUG:** Rituximab (R)
- **DRUG:** Cyclophosphamide (CTX)
- **DRUG:** Vincristin
- **DRUG:** Prednisolone

## Key facts

- **NCT ID:** NCT06594640
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-30
- **Primary completion:** 2026-06-30
- **Final completion:** 2027-07-30
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2025-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06594640

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06594640, "R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06594640. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*